top border
top border
Featured Programs
PD-L1 Expression as a Biomarker in RCC
The panelists, Nizar M. Tannir, MD, FACP; Carlos H. Barrios, MD; Susanne Osanto, MD, PhD; Daniel Heng, MD, MPH, FRCPC; and Paul Nathan, MBBS, PhD, FRCP, address PD-L1 expression as a potential biomarker for selecting renal cell carcinoma (RCC) treatment. View Now

In this segment, Dean F. Bajorin, MD, and Evan Y. Yu, MD, discuss atezolizumab in muscle-invasive bladder cancer. View Now

 

Featured Video

Hepatocellular Carcinoma (HCC):
Can We Improve Patient Survival?

Hepatocellular Carcinoma (HCC): Can We Improve Patient Survival?
Richard Finn, MD, Laura M. Kulik, MD, and Matthew S. Johnson, MD, FSIR, discuss the evolving systemic treatment paradigm for patients with advanced hepatocellular carcinoma. View now

Gina Columbus

Gina Columbus reports on the latest news in oncology in this week's edition of OncLive News Network.

Publication Bottom Border
Border Publication